Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 3
1998 5
1999 2
2000 1
2001 5
2002 6
2003 10
2007 2
2008 1
2010 2
2011 3
2012 2
2016 1
2017 2
2018 3
2019 1
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. Sehouli J, et al. Among authors: bogenrieder t. J Clin Oncol. 2011 Jan 10;29(2):242-8. doi: 10.1200/JCO.2009.27.8911. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115872 Clinical Trial.
Topotecan in cervical cancer.
Ackermann S, Beckmann MW, Thiel F, Bogenrieder T. Ackermann S, et al. Among authors: bogenrieder t. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1215-23. doi: 10.1111/j.1525-1438.2007.01003.x. Int J Gynecol Cancer. 2007. PMID: 17997795 Review.
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, Baumgartinger R, Adam PJ, Solca F, Kraut N, Nguyen HM, Corey E, Liu G, Sprenger CC, Plymate SR, Bogenrieder T. Weyer-Czernilofsky U, et al. Among authors: bogenrieder t. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. doi: 10.1158/1535-7163.MCT-19-0378. Epub 2020 Feb 13. Mol Cancer Ther. 2020. PMID: 32054790 Free article.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: bogenrieder t. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
The molecular pathology of cutaneous melanoma.
Bogenrieder T, Herlyn M. Bogenrieder T, et al. Cancer Biomark. 2010;9(1-6):267-86. doi: 10.3233/CBM-2011-0164. Cancer Biomark. 2010. PMID: 22112480 Review.
Non-reproducible sequence artifacts in FFPE tissue: an experience report.
Ofner R, Ritter C, Ugurel S, Cerroni L, Stiller M, Bogenrieder T, Solca F, Schrama D, Becker JC. Ofner R, et al. Among authors: bogenrieder t. J Cancer Res Clin Oncol. 2017 Jul;143(7):1199-1207. doi: 10.1007/s00432-017-2399-1. Epub 2017 Mar 17. J Cancer Res Clin Oncol. 2017. PMID: 28314930
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page